214 related articles for article (PubMed ID: 19210692)
1. Late onset Pneumocystis pneumonia in renal transplantation after long-term immunosuppression with belatacept.
Haidinger M; Hecking M; Memarsadeghi M; Weichhart T; Werzowa J; Hörl WH; Säemann MD
Transpl Infect Dis; 2009 Apr; 11(2):171-4. PubMed ID: 19210692
[TBL] [Abstract][Full Text] [Related]
2. Infection due to Pneumocystis jirovecii in haemodialysis.
Palma-Barrio R; Torres-de Rueda Á; Pizarro-León JL
Nefrologia; 2013; 33(5):742-3. PubMed ID: 24089172
[No Abstract] [Full Text] [Related]
3. Pneumocystis jirovecii pneumonia after rituximab therapy for antibody-mediated rejection in a renal transplant recipient.
Kumar D; Gourishankar S; Mueller T; Cockfield S; Weinkauf J; Vethanayagam D; Humar A
Transpl Infect Dis; 2009 Apr; 11(2):167-70. PubMed ID: 18803617
[TBL] [Abstract][Full Text] [Related]
4. Belatacept: in adult kidney transplant recipients.
Garnock-Jones KP
BioDrugs; 2012 Dec; 26(6):413-24. PubMed ID: 22928660
[TBL] [Abstract][Full Text] [Related]
5. Rationale for using belatacept in combination with sirolimus.
Wéclawiak H; Kamar N; Ould-Mohamed A; Cardeau-Desangles I; Rostaing L
Transplant Proc; 2010 Nov; 42(9 Suppl):S29-31. PubMed ID: 21095447
[TBL] [Abstract][Full Text] [Related]
6. Risk Evaluation and Outcome of Pneumocystis jirovecii Pneumonia in Kidney Transplant Patients.
Brakemeier S; Dürr M; Bachmann F; Schmidt D; Gaedeke J; Budde K
Transplant Proc; 2016 Nov; 48(9):2924-2930. PubMed ID: 27932109
[TBL] [Abstract][Full Text] [Related]
7. Belatacept: a novel immunosuppressive agent for kidney transplant recipients.
Charpentier B
Expert Rev Clin Immunol; 2012 Nov; 8(8):719-28. PubMed ID: 23167683
[TBL] [Abstract][Full Text] [Related]
8. Belatacept: a new era of immunosuppression?
El-Charabaty E; Geara AS; Ting C; El-Sayegh S; Azzi J
Expert Rev Clin Immunol; 2012 Aug; 8(6):527-36. PubMed ID: 22992146
[TBL] [Abstract][Full Text] [Related]
9. Biological agents in kidney transplantation: belatacept is entering the field.
Wéclawiak H; Kamar N; Ould-Mohamed A; Cardeau-Desangles I; Rostaing L
Expert Opin Biol Ther; 2010 Oct; 10(10):1501-8. PubMed ID: 20726688
[TBL] [Abstract][Full Text] [Related]
10. Profile of belatacept and its potential role in prevention of graft rejection following renal transplantation.
Gupta G; Womer KL
Drug Des Devel Ther; 2010 Dec; 4():375-82. PubMed ID: 21151624
[TBL] [Abstract][Full Text] [Related]
11. Belatacept utilization recommendations: an expert position.
Grinyó JM; Budde K; Citterio F; Charpentier B
Expert Opin Drug Saf; 2013 Jan; 12(1):111-22. PubMed ID: 23206310
[TBL] [Abstract][Full Text] [Related]
12. Pneumocystis jirovecii pneumonia 13 years post renal transplant following a recurrent cytomegalovirus infection.
Muhammad Iqbal AH; Lim SK; Ng KP; Tan LP; Chong YB; Keng TC
Transpl Infect Dis; 2012 Aug; 14(4):E23-6. PubMed ID: 22551151
[TBL] [Abstract][Full Text] [Related]
13. Belatacept: a new biologic and its role in kidney transplantation.
Su VC; Harrison J; Rogers C; Ensom MH
Ann Pharmacother; 2012 Jan; 46(1):57-67. PubMed ID: 22215686
[TBL] [Abstract][Full Text] [Related]
14. Analysis of USRDS: incidence and risk factors for Pneumocystis jiroveci pneumonia.
Neff RT; Jindal RM; Yoo DY; Hurst FP; Agodoa LY; Abbott KC
Transplantation; 2009 Jul; 88(1):135-41. PubMed ID: 19584693
[TBL] [Abstract][Full Text] [Related]
15. Belatacept-versus cyclosporine-based immunosuppression in renal transplant recipients with pre-existing diabetes.
Rostaing L; Neumayer HH; Reyes-Acevedo R; Bresnahan B; Florman S; Vitko S; Heifets M; Xing J; Thomas D; Vincenti F
Clin J Am Soc Nephrol; 2011 Nov; 6(11):2696-704. PubMed ID: 21921152
[TBL] [Abstract][Full Text] [Related]
16. Rejection treatment and cytomegalovirus infection as risk factors for Pneumocystis carinii pneumonia in renal transplant recipients.
Arend SM; Westendorp RG; Kroon FP; van't Wout JW; Vandenbroucke JP; van Es LA; van der Woude FJ
Clin Infect Dis; 1996 Jun; 22(6):920-5. PubMed ID: 8783687
[TBL] [Abstract][Full Text] [Related]
17. Costimulation targeting therapies in organ transplantation.
Gandhi AM; Fazli U; Rodina V; Qazi YA
Curr Opin Organ Transplant; 2008 Dec; 13(6):622-6. PubMed ID: 19060553
[TBL] [Abstract][Full Text] [Related]
18. Belatacept : a new biological agent for maintenance immunosuppression in kidney transplantation.
Arora S; Tangirala B; Osadchuk L; Sureshkumar KK
Expert Opin Biol Ther; 2012 Jul; 12(7):965-79. PubMed ID: 22564126
[TBL] [Abstract][Full Text] [Related]
19. Late-onset and atypical presentation of Pneumocystis carinii pneumonia in a renal transplant recipient.
Li JY; Yong TY; Grove DI; Coates PT
Clin Exp Nephrol; 2009 Feb; 13(1):92-5. PubMed ID: 18758701
[TBL] [Abstract][Full Text] [Related]
20. Aggressive immunosuppressant reduction and long-term rejection risk in renal transplant recipients with Pneumocystis jiroveci pneumonia.
Yang CY; Shih CJ; Yang WC; Lin CC
Exp Clin Transplant; 2012 Aug; 10(4):344-9. PubMed ID: 22765304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
